Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference
09:00am, Wednesday, 19'th Feb 2025
On-demand video webcast now available here ISELIN, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in t
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update
08:05am, Friday, 14'th Feb 2025
ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) resubmission on track to meet target of Q1 CY2025 LYTENAVA™ (bevacizumab gamma) on track for first commercial launches i
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
09:05am, Tuesday, 04'th Feb 2025
Dr. Jennifer Kissner, SVP Clinical Development, discusses the 12-week safety and efficacy results for NORSE EIGHT clinical trial
Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors
08:05am, Friday, 31'st Jan 2025
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd
ISELIN, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd
Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
09:05am, Wednesday, 22'nd Jan 2025
ISELIN, N.J., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingd
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
12:09pm, Thursday, 16'th Jan 2025
On Thursday, Outlook Therapeutics, Inc. OTLK completed the analysis of the complete 12-week safety and efficacy results for NORSE EIGHT evaluating ONS-5010 in wet age-related macular degeneration (wet
Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
06:00am, Thursday, 16'th Jan 2025
ISELIN, N.J., Jan. 16, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Outlook Therapeutics, or the Company) (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the E
Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment
09:15am, Wednesday, 08'th Jan 2025
Jedd Comiskey, Senior Vice President, Head of Europe, highlights the recent NICE recommendation of LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMD
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update
08:05am, Friday, 27'th Dec 2024
ISELIN, N.J., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea
Outlook Therapeutics® Streamlines Operations
04:30pm, Friday, 13'th Dec 2024
ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
08:05am, Wednesday, 04'th Dec 2024
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment
Outlook Therapeutics® Announces Executive Leadership Transition
04:30pm, Tuesday, 03'rd Dec 2024
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
02:31pm, Monday, 02'nd Dec 2024
NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK). Such investors are
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
11:31am, Thursday, 28'th Nov 2024
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
